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Renal damage due to urinary tract obstruction accounts for up to 30% of acute kidney injury in paediatrics and adults. Bilateral
ureteral obstruction (BUO) is associated with polyuria and reduced urinary concentrating capacity. We investigated the renal
handling of water and electrolytes together with the renal expression and the urinary excretion of the Na-K-Cl cotransporter
(NKCC2) after 1 (BUO-1), 2 (BUO-2), and 7 (BUO-7) days of release of BUO. Immunoblotting and immunohistochemical studies
showed that NKCC2 expression was upregulated in apical membranes both from BUO-2 and from BUO-7 rats. The apical
membrane expression, where NKCC2 is functional, may be sufficient to normalize water, potassium, sodium, and osmolytes
tubular handling. NKCC2 abundance in homogenates andmRNA levels of NKCC2 was significantly decreased in almost all groups
suggesting a decrease in the synthesis of the transporter. Urinary excretion of NKCC2 was increased in BUO-7 groups. These data
suggest that the upregulation in the expression of NKCC2 in apical membranes during the postobstructive phase of BUO could
contribute to improving the excretion of sodium and consequently also the excretion of potassium, osmolytes, and water.Moreover,
the increase in urinary excretion of NKCC2 in BUO-7 group could be a potential additional biomarker of renal function recovery.
1. Introduction
Renal damage due to urinary tract obstruction accounts for
up to 30% of acute kidney injury in paediatrics [1]. Urinary
tract obstruction is characterized by a significantly reduced
capacity of kidney to regulate urinary excretion of water
and sodium [2–4]. The loss of urinary concentrating ability
involves all nephron segments and the underlying patho-
physiology is intricate [4]. The active transport of sodium
chloride in the thick ascending limb of Henle’s loop occurs
mainly through theNa-K-2Cl cotransporter type 2 (NKCC2).
Thus, corticomedullary concentration gradient is created.
This interstitial hypertonicity in the renal medulla leads to
water absorption through the aquaporin-2 (AQP2) water
channel in the collecting duct in the presence of vasopressin
[5, 6].
Many studies in animalmodels have shown that alteration
in sodium transporters plays important roles in disorders of
sodium and water balance, including lithium-induced
nephrogenic diabetes insipidus [7], vitamin D-
induced hypercalcemia [8], and liver cirrhosis [9]. The
pathophysiology of urine concentrating ability after release
of bilateral ureteral obstruction (BUO) is complicated and
themolecularmechanisms involved are not yet fully clarified.
Sodium transporter proteins, such as Na+/H+ exchanger
type 3 (NHE3), NKCC2, and thiazide-sensitive Na+-Cl−
cotransporter, are excreted in urine as previous studies have
demonstrated [10]. However, the presence in urine of integral
membrane proteins, such as NKCC2 in BUO rats, has not yet
been elucidated and it seems likely to be important in clinical
trials.
The aim of this study was to examine the time course of
renal NKCC2 expression after the release of BUO employing
Western blotting (in homogenates and apical membranes),
immunohistochemistry, and RT-PCR techniques. In addi-
tion, the influence of NKCC2 expression on renal function
parameters and urinary excretion of NKCC2 after release of
ureteral occlusion was also evaluated.
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2. Materials and Methods
2.1. Ethical Approval. Male Wistar rats 110 to 130 days old
were used throughout the study. Animals were allowed free
access to a standard laboratory chow and tap water and
were housed in an environment of constant temperature
and humidity with regular light cycles (12 h) during the
experiments. Animals were cared for in accordance with
principles and guidelines for the care and use of laboratory
animals, recommended by the National Academy of Sciences
and published by the National Institute of Health (NIH
publication 7th edition revised 1996) and recommended by
regulations of the local ethics committee. All experimental
procedures were approved by the Faculty of Biochemical and
Pharmaceutical Sciences Institutional Animal Care and Use
Committee.
2.2. Experimental Animals. Ureters’ ligation and release were
performed as previously described [11–14]. The abdominal
cavity was opened, and a nontraumatic microvascular clamp
was placed on both proximal ureters. After closure of the
abdomen, the animals were kept for 24 hours while they were
given food and water ad libitum. The ureteral obstruction
was released after 24 h and the rats, referred to as bilateral
ureteral obstructed ones, were kept alive for different times.
Corresponding control groups, referred to as sham group,
were treated the same, except that no ureteral obstructionwas
performed. Rats were anaesthetized with sodium thiopental
(70mg/kg b.w., i.p.).
The following groups were studied:
(i) BUO-1 (𝑛 = 5); experimental studies were performed
at 1 day after ureteral release.
(ii) BUO-2 (𝑛 = 6): experimental studies were performed
at 2 days after ureteral release.
(iii) BUO-7 (𝑛 = 5): experimental studies were performed
at 7 days after ureteral release.
As all the tested parameters in sham groups (1, 2, and 7
days after sham surgery) were similar, we decided to consider
them as one group (unified sham) to facilitate the analysis of
the results.
Different sets of experimental animals were used for
biochemical determinations, renal clearance studies, prepa-
ration of homogenates (H), and apical membranes (AM) for
Western blotting studies, immunohistochemical studies, and
mRNA isolation (for RT-PCR studies).
2.3. Biochemical Determinations. On the day of the experi-
ment, blood was withdrawn from femoral artery and urine
was collected by bladder puncture as previously described
[12–14]. Serum samples were used to measure urea and crea-
tinine levels as indicative parameters of global renal function.
Urine samples were centrifuged at 1000×g for 10 minutes to
discard whole cells and detritus and the supernatant were
used for evaluating creatinine concentration and NKCC2
abundance. Serum urea and creatinine levels, as well as
urine creatinine concentrations, were determined employing
commercial kits (Wiener Laboratory, Rosario, Argentina).
2.4. Renal Clearance Studies. These studies were performed
as previously described [13–15]. The glomerular filtration
rate (GFR) was calculated from the clearance of inulin.
The ratio urine to plasma osmolality (U/P), the fractional
excretion of water (FE%H2O), sodium (FE%Na), potassium
(FE% K), and osmolytes (FE% Osm) were also calculated by
conventional formulae for each animal. Inulin concentrations
in plasma and urine were determined as previously described
[12–15]. Sodium and potassiumweremeasured by flame pho-
tometry and the volume of urine by gravimetry. Osmolalities
were determined in a freezing point osmometer (Osmomat
030, Berlin, Germany).
2.5. Preparation of Apical Membranes (AM). All rats were
anaesthetized as previously described and kidneys were
rapidly removed. The renal tissue was cleaned, dried,
weighed, and placed in saline. The kidney samples were
dissected in cortex and medulla. Medulla samples included
outer and inner medulla. AM were isolated from renal
cortex and medulla by Mg/EDTA precipitation as previously
described [16]. The AM pellets obtained were resuspended
in 50mM mannitol plus 10mM Tris-HEPES buffer (pH
7.40), and total protein concentrations in these membrane
fractions were measured as previously described [12–14].
Each preparation represents cortical and medullary tissue
from four animals. Four preparations were obtained for each
experimental group.
2.6. Electrophoresis and Immunoblotting. Homogenate
(50 𝜇g proteins), AM (40 𝜇g proteins), and urine samples
(10 𝜇L) were boiled for 3min in the presence of 1% 2-
mercaptoethanol/2% SDS (sodium dodecyl sulphate).
Samples were applied to a 5% polyacrylamide gel, separated
by SDS-PAGE, and then electroblotted to nitrocellulose
membranes as previously described [12–18]. To verify equal
protein loading and transfer between lanes, Ponceau Red
and antibody against human 𝛽-actin were used as previously
reported [12–18]. The nitrocellulose membranes were
incubated 1 h with 5% nonfat dry milk in phosphate buffer
saline containing 0.1% Tween 20 (PBST). After being rinsed
with PBST, the membranes were then incubated overnight
at 4∘C with a commercial polyclonal antibody against
rat NKCC2 (NKCC21-A; 1.25 𝜇g/mL; Alpha Diagnostic
International, San Antonio, USA) or a commercial mouse
monoclonal antibody against human 𝛽-actin (at a dilution
of 1 : 800; Alpha Diagnostic International, San Antonio, TX,
USA). Blots were processed for detection using a commercial
kit (ECL Enhanced Chemiluminescence System, Thermo
Scientific, Rockford, USA). The immunoreactive bands were
quantified using the Gel-Pro Analyzer (Media Cybernetics,
Silver Spring, USA) software in all Western blotting studies.
For densitometry of immunoblots, samples from obstructed
kidneys were run on each gel with corresponding sham
kidneys. NKCC2 abundance was normalized to 𝛽-actin.
The relative protein expression for NKCC2 was expressed as
percentage of the mean sham value for each gel.
2.7. RNA Isolation andRT-PCR. Total RNAwas isolated using
the TriZOL reagent (Invitrogen, Carlsbad, USA) according
BioMed Research International 3
Table 1: Creatinine and urea plasma levels, urine volume, and urine to plasma osmolality ratio (U/P) in Sham, BUO-1, BUO-2, and BUO-7
rats.
Sham (𝑛 = 16) BUO-1 (𝑛 = 5) BUO-2 (𝑛 = 6) BUO-7 (𝑛 = 5)
Plasma creatinine (mg/dL) 0.35 ± 0.03 1.40 ± 0.20a,c,d 0.97 ± 0.12a,b,d 0.51 ± 0.06b,c
Plasma urea (g/L) 0.56 ± 0.09 2.91 ± 0.67a,c,d 1.78 ± 0.61a,b,d 0.60 ± 0.09b,c
Urine volume (𝜇L/min/100 g b.w) 5.01 ± 0.74 11.60 ± 1.12a,c,d 7.95 ± 1.17b 5.23 ± 0.52b
U/P 4.19 ± 0.41 1.83 ± 0.21a,d 2.10 ± 0.17a,d 3.79 ± 0.25b,c
Results are expressed as means ± SE. BUO: bilateral ureteral obstruction; BUO-1: 1 day after releasing of BUO; BUO-2: 2 days after releasing of BUO; BUO-7:
7 days after releasing of BUO; sham: sham-operated rats. Statistical comparison between experimental groups was made by one-way ANOVA plus Newman-
Keuls. a𝑃 < 0.05 versus sham, b𝑃 < 0.05 versus BUO-1, c𝑃 < 0.05 versus BUO-2, and d𝑃 < 0.05 versus BUO-7.
to the manufacturer’s instructions. RNA was dissolved in
DEPC-treated water and kept at −80∘C until use. Reverse
transcription of 5𝜇g of total RNA was performed with oligo-
dT primer, and cDNA samples were stored at −20∘C until
assayed. NKCC2 and 18S, as housekeeping gene, cDNAs were
amplified with specific antisense primers that shared the
same sense primer. Sequences were as follows: 5󸀠-ACCAAG-
AACCTCCCTCCTGT-3󸀠 (NKCC2 sense), 5󸀠-TCGGAC-
ACCAAGGTACAACA-3󸀠 (NKCC2 antisense) and 5󸀠-CGC-
GGTTCTATTTTGTTGGT-3󸀠 (18S sense), 5󸀠-AGTCGG-
CATCGTTTATGGTC-3󸀠 (18S antisense). The thermoprofile
for SYBR RT-PCR was 94∘C for 2min for denaturation,
followed by 23 cycles for both NKCC2 and 18S, 94∘C for 15 s,
and 55∘C for 30 s and 1min. RT-PCR products were then
resolved on a 2% agarose gel stained with Sybr Safe and
bands were visualized using a high performance ultraviolet
transilluminator (Safe Imager, Invitrogen, Carlsbad, USA).
Images of the RT-PCR Syber Safe agarose gels were acquired
and quantification of the optical density (OD) of bands was
performed using the Gel-Pro Analyzer (Media Cybernetics,
Silver Spring, USA) software. Results were expressed as the
ratio between the intensities of NKCC2 OD and 18S OD.
2.8. Immunohistochemistry. As previously described [13–
18], rats were briefly perfused with saline, followed by
perfusion with periodate-lysine-paraformaldehyde solution
(0.01M NaIO4, 0.075M lysine, 0.0375M phosphate buffer,
with 2% paraformaldehyde, pH: 6.20), through a can-
nula inserted in the abdominal aorta. Kidney slices were
immersed in periodate-lysine-paraformaldehyde solution at
4∘C overnight. The tissue was embedded in paraffin. Paraffin
sections were cut. After deparaffining, the sections were
incubated with 3% H2O2 for 15min (to eliminate endoge-
nous peroxidase activity) and then with blocking serum for
30min. The sections were then incubated with noncommer-
cial polyclonal antibody against NKCC2 (dilution 1 : 1000)
overnight at 4∘C kindly provided by Dr. Mitsunobu Matsub-
ara (Division ofMolecularMedicine, Centre for Translational
and Advanced Animal Research, Tohoku University School
of Medicine, Aoba-ku, Sendai, Japan) [19]. The sections
were rinsed with Tris-buffer saline containing 0.1% Tween
20 (TBST). The sections were incubated with horseradish
peroxidase- (HRP-) conjugated secondary antibody against
rabbit immunoglobulin for 1 h. To detect HRP labeling,
a commercial kit was used (DAB Substrate Kit, Zymed
Laboratories Inc., San Francisco, USA). The sections were
counterstained with hematoxylin before being examined
under a lightmicroscope. Two blinded investigators indepen-
dently examined the respective samples.
2.9. Materials. Chemicals were purchased from Sigma (St.
Louis, USA) and were of analytical pure grade. Urea and
creatinine kits were from Wiener Lab, Argentina. The non-
traumatic microvascular clamps (Schwartz clamp strong
ang, ref 26-1043) were manufactured by Miltex Instrument
Company, Inc., Bethpage,NY,USA, andwere purchased from
Thomas Scientific, NJ, USA.
2.10. Statistical Analysis. All results are expressed as mean
± standard error (SE). Statistical differences between groups
were evaluated by one-way ANOVA followed by the
Newman-Keuls test. 𝑃 < 0.05 was considered statistically
significant. For these analyses GraphPad (San Diego, USA)
software was used.
3. Results
Table 1 shows urea and creatinine concentration in plasma,
the urine to plasma osmolality ratio (U/P), and the urine vol-
ume in all experimental groups. In BUO-1 a highly significant
increase in both urea and creatinine plasma levels indicated
the presence of acute renal failure in our experimental model.
BUO-2 group showed a partial recovery of these parameters
but still remained above normal values thus confirming acute
renal failure in these animals too. Early time after release of
BUO (BUO-1 and BUO-2) resulted in an increase in urine
output and parallel reduction in urine osmolality and U/P,
indicating an impairment of urinary concentrating capacity.
At 7 days after release of BUO, full recovery to normal values
was found in all of these parameters.
BUO release was also associated with altered renal elec-
trolytes and water management. One day after the release
of BUO, there were significant increases in the fractional
excretion of water (FE% H2O), potassium (FE% K), and
osmolytes (FE% Osm). Two days after the release of BUO all
of these parameters persisted elevated and returned to normal
levels after 7 days of releasing the obstruction (Table 2). On
the other hand, the fractional excretion of sodium (FE%
Na) was recovered to control levels at day 2 of releasing.
However, a statistical comparison between BUO-2 and sham
groupswas also performedby standard unpaired t-test, which
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Table 2: Changes in the fractional excretion of H2O (EF% H2O), K (EF% K), Osm (EF% Osm), and Na (EF% Na) in Sham, BUO-1, BUO-2,
and BUO-7 rats.
Sham (𝑛 = 16) BUO-1 (𝑛 = 5) BUO-2 (𝑛 = 6) BUO-7 (𝑛 = 5)
EF% H2O 0.86 ± 0.12 9.86 ± 1.57
a,c,d 5.04 ± 0.93a,b,d 0.89 ± 0.10b,c
EF% K 30.5 ± 2.5 87.6 ± 5.5a,d 78.2 ± 8.2a,d 39.4 ± 3.1b,c
EF% Osm 2.88 ± 0.12 15.14 ± 2.01a,c,d 9.81 ± 0.82a,b,d 3.29 ± 0.28b,c
EF% Na 1.28 ± 0.09 50.3 ± 11.6∗,a,c,d 2.96 ± 0.15∗,b 1.46 ± 0.08b
Values are presented as means ± SE. BUO: bilateral ureteral obstruction; BUO-1: 1 day after releasing of BUO; BUO-2: 2 days after releasing of BUO; BUO-7: 7
days after releasing of BUO; Sham: sham-operated rats. Statistical comparison between experimental groups was made by a standard unpaired t-test ∗𝑃 < 0.05
versus Sham; or one-way ANOVA plus Newman-Keuls a𝑃 < 0.05 versus Sham, b𝑃 < 0.05 versus BUO-1, c𝑃 < 0.05 versus BUO-2, and d𝑃 < 0.05 versus BUO-
7.
showed that there was a significant difference between them
(Table 2).
In the present study, we used semiquantitative immun-
oblotting, immunohistochemistry, and RT-PCR to investi-
gate expression changes of renal NKCC2 for a period of time
after release of bilateral ureteral obstruction.
Western blotting in homogenates and AM from kidney
cortex and medulla from sham-operated and BUO rats
showed signals for NKCC2 (Figure 1). The expression of
NKCC2 in cortex homogenate was reduced after 1-day release
of BUO and persisted downregulated up to 7 days after
release. NKCC2 expression level in AM of kidney cortex was
not different between bothBUO-1 andBUO-2 comparedwith
sham-operated animals. This parameter in BUO-7 rats, in
contrast, was strongly increased. Figure 1(c) shows increased
NKCC2 expression in kidney medulla homogenates from
BUO-1 rats. Two days after releasing the obstruction there
was an important decrease in this parameter that tended to
return to normal levels at 7 days after release of BUO. In
Figure 1(d), it is possible to observe that NKCC2 expression
level in kidney medulla of AM was significantly decreased in
BUO-1 animals but increased in both BUO-2 andBUO-7 rats.
We have also examined NKCC2 expression in sham and
BUO rats using immunohistochemistry (Figure 2). NKCC2
was decreased in BUO-1 in cortex and medulla (Figure 2(b)).
Immunohistochemical observations revealed a predominant
apical NKCC2 localization, two and seven days after release
of the obstruction (Figures 2(c) and 2(d)); these results
confirmed the pattern observed for immunoblotting.
To investigate the molecular mechanism of the downreg-
ulation of NKCC2 protein expression in renal medullae and
cortex, NKCC2 mRNA was quantified by RT-PCR in BUO
and sham animals (Figure 3). Interestingly, NKCC2 mRNA
was significantly decreased in the medulla and cortex of all
BUO rats.
NKCC2 abundance in urine was related to urinary cre-
atinine concentrations to correct variations in urine output
as previously described for other urinary transporters and
enzymes [16–18, 20–22]. Measurements of biomarker abun-
dance themselves are insufficient because normal physio-
logical variations in water excretion may dilute or concen-
trate urinary proteins. As the creatinine is excreted in the
urine at relatively constant rate, it is used to normalize the
urinary excretion of a particular protein. Urinary excretion
of NKCC2 was almost three times higher in BUO-7 group
compared with other groups studied, as shown in Figure 4.
4. Discussion
The kidney disease caused by impaired flow of urine or
tubular fluid is known as obstructive nephropathy. It is a
common disorder that occurs at all ages [2, 4]. Up to 30%
of acute kidney injury in pediatrics may be explained by
kidney injury due to urinary tract obstruction, especially in
nephrolithiasis [1, 23].
In experimentalmodels of ureteral obstruction, in several
species, it has been verified that natriuresis and vasopressin-
resistant polyuria appeared after ureteral obstruction in
patients [2, 24]. Moreover, in vitro studies have demonstrated
a decrease in reabsorption of water and salt in the proximal
tubule, the distal convoluted tubule, and the collecting duct
after release of obstruction [25, 26]. In the present study we
have evaluated the changes in renal expression and in urinary
excretion of NKCC2 during the postobstructive phase of
bilateral ureteral obstruction. Emphasis was placed on the
changes during the postobstructive phase of the release of
bilateral ureteral occlusion in the expression of renal NKCC2
assayed by Western blotting and immunohistochemistry, its
relationship with NKCC2 urinary excretion and with renal
functional changes.
Apical NKCC2 and basolateral Na,K-ATPase are major
sodium transporters responsible for active NaCl transport
in the thick ascending limb of Henle’s loop (mTAL). In
particular, NKCC2 cotransporter in the mTAL is partly
responsible for the generation of a high osmolality in the
interstitium by performing countercurrent multiplier, which
is dependent on NaCl reabsorption [4].
The abundance of major renal sodium transporters/
cotransporters and transporters of urea was reduced along
the nephron in response to unilateral ureteral obstruction
(UUO) [27, 28]; however, this model with one unobstructed
hyperfunctioning kidney is not directly comparable to the
present model of BUO. BUO and release of BUO in rats
were associated with decreased expression of the major renal
sodium transporters along the nephron and collecting ducts.
In fact, early studies showed that expression of NKCC2 in
samples of whole kidney was drastically reduced at day 3 after
release of BUO [29]. In this regard, we observed in this study
a decrease in the expression of NKCC2 both in cortex and
in medulla homogenates at day 2 after release of BUO, which
might precede the dramatic decrease at day 3 after release of
BUO described by Li et al. [29]. It is important to mention
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Figure 1: Renal cortex homogenates ((a) 40 𝜇g proteins) and apical membranes ((b) 30𝜇g proteins) and renal medullae homogenates ((c)
40 𝜇g proteins) and apical membranes ((d) 30𝜇g proteins) from kidneys of sham and BUO rats were separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (5%) and blotted onto nitrocellulose membranes. NKCC2 (150 kDa) was identified using commercial
polyclonal antibodies as described in Section 2. Kaleidoscope-prestained standards of molecular mass (Mr) corresponding to myosin
(206.4 kDa) and to carbonic anhydrase (38.9 kDa) are indicated in the left of the figure. Sham levels were set at 100%. Each column represents
mean ± SE from experiments carried out in triplicate on four different cortex and medulla homogenates and apical membranes preparations
for each experimental group. A𝑃 < 0.05 versus sham, B𝑃 < 0.05 versus BUO-1, C𝑃 < 0.05 versus BUO-2, and D𝑃 < 0.05 versus BUO-7.
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Figure 2: Immunohistochemistry forNKCC2 in cortex andmedulla
kidney of sham (a) and BUO (b–d) rats. Serial sections from
each rat kidney were stained with noncommercial polyclonal anti-
NKCC2 antibodies as described in Section 2. Immunoperoxidase
microscopy demonstrated association of NKCC2 labeling with
apical membrane of thick ascending limb of Henle’s loop of sham
rats (a). No difference in NKCC2 labeling was found in cortex of
BUO-1 (b) and BUO-2 (c); increased labeling was seen in apical
membrane inBUO-7 (d) kidneys.NKCC2 labeling in renalmedullae
was reduced in BUO-1 (b) and increased apical localization of
NKCC2 in BUO-2 and BUO-7 (c-d) was observed. These figures
are representatives of typical samples from four rats. Magnification
×400.
that our present work emphasizes the NKCC2 expression in
the apical membrane where the protein is functional.
The present study demonstrated that after release of
ureteral obstruction follows a marked diuresis characterized
by massive loss of water, sodium, and other solutes. In this
regard, NKCC2 expression was significantly downregulated
in cortical and medullary homogenates in almost all groups
except for renal medulla from BUO-1 group. Increased
abundance of NKCC2 in medullary homogenates of this
group could be caused by a decrease in its degradation with
the aim of reaching a compensation to the sudden decrease
of this transporter in renal cortex. This downregulation of
NKCC2 expression would cause a profound increase in the
urinary excretion of sodium and chloride (i.e., up to 25%
of the filtered load of Na). The consequent alteration of the
transepithelial potential difference in the thick ascending
limbwill also result in a significant increase in the excretion of
calcium andmagnesium.The increased delivery of sodium to
the distal tubule will augment the depolarization of the lumi-
nal membrane of this nephron segment which will facilitates
potassium urinary excretion. The reduced sodium chloride
reabsorption in the thick ascending limb due to the decrease
of NKCC2 expression will also interfere with the critical
step in the mechanism that produces a hypertonic medullary
interstitium, causing an increase in the elimination ofwater in
urine [4].
In cortical apical membrane, NKCC2 expression
increased in BUO-7 group. NKCC2 expression also
increased at 2 and 7 days after release of BUO in apical
membranes of medulla. These results could explain, at least
in part, the recovery of the fractional excretion of sodium,
and consequently potassium, osmolytes, and water observed
in BUO-7 group.
The downregulation of the expression of NKCC2 protein
in homogenates from BUO kidneys could be caused by the
decrease in its synthesis, the increase in its degradation,
the liberation of intracellular and apical membrane fractions
into tubular fluid, or a consequence of cell shedding. More-
over, increased NKCC2 abundance in the apical membrane
together with previous results in homogenates suggests alter-
ations in the intracellular distribution of this transporter.
An alteration in NKCC2 trafficking might be caused by
an increased recruitment of preformed transporters into
the membranes or an inhibition in the internalization of
membrane transporters.
Furthermore, immunohistochemical study confirms that
there was an increase in NKCC2 expression at apical plasma
membrane domains of thick ascending limb cells of BUO
compared to sham-operated rats.
We have also observed that the level of NKCC2 mRNA
as well as protein abundance in homogenate in cortex
and medulla decreased after release of BUO, indicating
a downregulation at transcriptional level. However, other
mechanisms mentioned above cannot be excluded.
Measurements of renal excretion of different carrier
proteins are exploited for the study of certain disease states
[16, 22, 30, 31]. It has been demonstrated that Na+ transporter
proteins such as NKCC2 are excreted in the urine of normal
rats in detectable quantities [10]. NKCC2 excretion in urine
of sham and BUO rats was determined.The initial low-speed
centrifugation was performed to remove whole cells, so it
is unlikely that the appearance of NKCC2 cotransporter in
urine is due to sloughing of whole cells. The presence of this
cotransporter in urine may be exploitable in clinical studies
as a potentialmarker of recovery after release of BUObecause
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Figure 3: mRNA levels of NKCC2 cotransporter in cortex (a) and medulla (b) of sham and BUO rats. Total RNA was isolated and NKCC2
and 18SmRNAwere assessed by RT-PCR analysis. Relative mRNA levels were quantitated, and NKCC2 levels were normalized to 18SmRNA.
Ratios are represented in graphical form, and the data are representative of four experiments. A𝑃 < 0.05 versus sham, B𝑃 < 0.05 versus BUO-1,
C
𝑃 < 0.05 versus BUO-2, and D𝑃 < 0.05 versus BUO-7.
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Figure 4: Urinary excretion of NKCC2 in sham and BUO rats. Urine samples were separated by SDS-PAGE (8.5%) and blotted onto
nitrocellulose membranes. NKCC2 was identified using commercial polyclonal antibody as described in Section 2. The densitometric
quantification of urine NKCC2 immunoblotting is expressed as the percentage of a ratio of arbitrary units relative to urinary creatinine
concentration for each sample. Sham levels were set at 100%. Results are expressed as mean values ± SE. A𝑃 < 0.05 versus sham, B𝑃 < 0.05
versus BUO-1, C𝑃 < 0.05 versus BUO-2, and D𝑃 < 0.05 versus BUO-7.
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we found an important increase in NKCC2 urinary excretion
in BUO-7 group. It could also help understand the whole
scene about the impaired ability to concentrate urine during
postobstructive phase of bilateral ureteral occlusion.
5. Conclusion
Data from this study suggest that the upregulation in NKCC2
expression in apical membranes during the postobstructive
phase of bilateral ureteral occlusion could improve the excre-
tion of sodium and consequently the excretion of potassium,
osmolytes, and water. Moreover, the increase in urinary
excretion of NKCC2 in BUO-7 group could be a potential
additional biomarker of renal function recovery, suitable
to complete the panel of biomarkers currently compiled to
evaluate the onset and recovery of obstructive nephropathy.
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